BNP Paribas Financial Markets’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

BNP Paribas Financial Markets’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-31	Closed	-$1.66K	–	3650
2016 Q1	$1.66K	Sell	31 -8,077	-100%	-$596K	﹤0.01%	2441
2015 Q4	$916K	Sell	8,108 -2,691	-25%	-$296K	﹤0.01%	1136
2015 Q3	$1.27M	Buy	10,799 +4,390	+68%	+$573K	﹤0.01%	975
2015 Q2	$496K	Buy	6,409 +2,623	+69%	+$172K	﹤0.01%	1345
2015 Q1	$219K	Sell	3,786 -8,214	-68%	-$349K	﹤0.01%	1539
2014 Q4	$387K	Sell	12,000 -5,333	-31%	-$160K	﹤0.01%	1199
2014 Q3	$424K	Buy	17,333 +1,125	+7%	+$22.9K	﹤0.01%	1590
2014 Q2	$287K	Buy	16,208 +4,208	+35%	+$67.7K	﹤0.01%	1700
2014 Q1	$198K	Buy	12,000 +11,672	+3,559%	+$226K	﹤0.01%	1798
2013 Q4	$5.5K	Buy	+328	New	+$4.54K	﹤0.01%	3038
2013 Q3	–	Sell	-11,244	Closed	-$62.9K	–	2905
2013 Q2	$62.9K	Buy	+11,244	New	+$68.1K	﹤0.01%	2630

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

BNP Paribas Financial Markets's ANAC Position: Q2 2016 in Review

BNP Paribas Financial Markets sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 31 shares — an estimated $1.66K sold.

BNP Paribas Financial Markets first reported a position in ANAC in Q2 2013 and held it in 11 quarters. The position peaked at $1.27M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

BNP Paribas Financial Markets reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
BNP Paribas Financial Markets sold 31 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $1.66K.
BNP Paribas Financial Markets first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 11 quarters.
BNP Paribas Financial Markets's ANACOR PHARMACEUTICALS INC COM position peaked at $1.27M in Q3 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2016, filed 6 Jul 2016.